New Delhi: Phase 2 and 3 clinical trials for the Russian COVID-19 vaccine Sputnik V commenced in India on Tuesday. Russian Direct Investment Fund (RDIF) and Dr Reddy’s Laboratories on Tuesday announced that they have commenced adaptive Phase 2 and 3 clinical trials for the coronavirus vaccine. Also Read - RDIF, Hetero Agree to Produce Over 100 Million Doses of Sputnik V Vaccine in India
Russia became the first country to register the world’s first Covid-19 vaccine on August 11. Sputnik V was developed by the Gamaleya National Research Centre for Epidemiology and Microbiology of the Russian Healthcare Ministry. Also Read - Sputnik V Vaccine 95% Effective, Says Russia; Single Dose to Cost Less Than $10 For Global Markets
The Sputnik V vaccine is based on a well-studied human adenoviral vector platform that had proven safe and effective with no long-term side effects in more than 250 clinical trials globally conducted during the past two decades (while the history of use of human adenoviruses in vaccine development started in 1953). More than 100,000 people have received approved and registered drugs based on the human adenoviral vectors. Also Read - Russia's Sputnik V To Cost Lower Than Pfizer, Moderna's COVID Vax
Last month, Russia said that its vaccine Sputnik V is 92 per cent effective at protecting people from COVID-19, according to the first interim analysis.
“The Sputnik V vaccine efficacy amounted to 92 per cent (calculation based on the 20 confirmed Covid-19 cases split between vaccinated individuals and those who received the placebo),” the RDIF said in a statement.
Sputnik V vaccine against Covid-19 will be tested in India on 100 volunteers, the Indian Central Drugs Standard Control Organisation’s Drug Controller General (DCGI) told Sputnik in October.
DCGI has granted permission to pharmaceutical giant Dr Reddy’s Laboratories for conducting tests.
(With ANI inputs)